Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2
Recruiting
- Conditions
- Relapsed or Refractory Peripheral T-cell Lymphoma
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2025-03-11
- Target Recruit Count
- 33
- Registration Number
- NCT05833724
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
Phase 1
Terminated
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2025-03-11
- Target Recruit Count
- 7
- Registration Number
- NCT05770882
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
News
No news found